Analysis of differences in response to long-acting growth hormone therapy and influencing factors between patients with idiopathic short stature (ISS) and growth hormone deficiency (GHD).

Long-acting growth hormone [pegylated recombinant human growth hormone (PEG-rhGH)] is increasingly used for pediatric short stature, yet its differential effects between growth hormone deficiency (growth hormone deficiency) and idiopathic short stature (idiopathic short stature) remain unclear.

This study aims to compare the 52-week efficacy and safety of PEG-rhGH in prepubertal children with growth hormone deficiency versus idiopathic short stature within a Chinese clinical cohort.